Biotech Boom Playbook, Part Two: The Structure
The degree to which a compelling biotech story is able to create lift in the equities market, and sustain that
Read moreThe degree to which a compelling biotech story is able to create lift in the equities market, and sustain that
Read moreBetween the Shroom Boom and COVID-19, the tables in the biotech wing of the micro-cap casino are seeing quite a
Read moreWelcome! If you are reading this, you have likely decided you would like to go beyond the headlines and learn
Read moreThis is the fourth installment in this guide to utilizing Sedar. You can find parts one, two and three here.
Read moreCongratulations! If you’ve been following along (see Part 1 and Part 2), you’ve now made it to your target company’s
Read moreWelcome back! The first step to using SEDAR is figuring out how to find the information that will help you
Read moreWelcome! If you are reading this, you have likely decided you would like to go beyond the headlines and learn
Read moreIt has come to the point at which we’re trying to figure out what’s going on, and the best way
Read moreIn the run-up to the legalization of adult-use cannabis, cannabis companies across Canada rapidly expanded their operations in preparation for
Read moreLimited Disclosures Risk Signaling Poor Financial Health to Analysts and Investors The ‘accounts receivable to sales’ ratio is one of
Read more